Vasculox, Inc.

Saint Louis, MO 63108

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $3.64MM
First Award Date 06/15/09
Most Recent Award Date 08/01/14

Key Personnel

Last Name Name Awards Contact
Toy-Manning Pamela Ann Toy-Manning 6
Frazier William A Frazier 2

8 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 08/01/14 - 07/31/15

DESCRIPTION (provided by applicant): Organ transplantation is a lifesaving option for those with end stage renal disease. In spite of many improvements in organ procurement, transplant procedures and immune suppression, the damage done by ischemia-reperfusion injury (IRI) remains problematic, leading to primary graft nonfunctional, delayed graft...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 09/29/13 - 07/31/14

DESCRIPTION (provided by applicant): Organ transplantation is a lifesaving option for those with end stage renal disease. In spite of many improvements in organ procurement, transplant procedures and immune suppression, the damage done by ischemia-reperfusion injury (IRI) remains problematic, leading to primary graft nonfunctional, delayed graft...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-12-089
Budget: 09/17/13 - 08/31/14

DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a "don't eat me" signal to macrophages via SIRPa, an inhibitory rec...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 05/01/13 - 04/30/14

DESCRIPTION (provided by applicant): Vasculox, Inc. is developing a humanized anti-CD47 mAb for reducing ischemia-reperfusion injury (IRI) in organ transplantation. In spite of improvements in surgical technique, organ preservation and immunosuppression, IRI remains a serious limitation and is responsible for delayed graft function, initial graf...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 05/01/12 - 04/30/13

DESCRIPTION (provided by applicant): Vasculox, Inc. is developing a humanized anti-CD47 mAb for reducing ischemia-reperfusion injury (IRI) in organ transplantation. In spite of improvements in surgical technique, organ preservation and immunosuppression, IRI remains a serious limitation and is responsible for delayed graft function, initial graf...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 08/01/11 - 07/31/13

DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. While there have been many recent strides in organ procurement, preservation and follow-up immune suppression, preven...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/01/09 - 08/31/11

DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. Current practice involves "donor preconditioning" to stabilize organs and tissues for transplant in attempts to incre...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 06/15/09 - 05/31/11

DESCRIPTION (provided by applicant): Nitric oxide (NO) is a critical regulator of cardiovascular physiology, coordinating the activities of the endothelium, the vessel wall and circulating cells to optimize the flow of blood and oxygen to tissues. Increasing the bioavailability of NO should provide therapeutic benefit in the treatment of many di...